BIOMERICA INC (BMRA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 05-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue TTM

0 7M 14M 21M Q4 '21: 7.2M Q1 '22: 7.3M Q2 '22: 10.6M Q3 '22: 14.6M Q4 '22: 18.9M Q1 '23: 19.2M Q2 '23: 16.1M Q3 '23: 9.5M Q4 '23: 5.3M Q1 '24: 5.4M Q2 '24: 5.5M Q3 '24: 5.4M Q4 '24: 5.4M Q1 '25: 5.5M Q2 '25: 5.6M Q3 '25: 5.7M Q4 '25: 5.3M Q1 '26: 4.9M Q2 '26: 4.5M Q3 '26: 4.3M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Gross Profit TTM

0 1.5M 3M 4.5M Q4 '20: 1.7M Q1 '21: 1.5M Q2 '21: 1.3M Q3 '21: 1M Q4 '21: 366.3K Q1 '22: 159.2K Q2 '22: 622.3K Q3 '22: 2.4M Q4 '22: 3M Q1 '23: 3M Q2 '23: 2.6M Q3 '23: 1M Q4 '23: 446K Q1 '24: 913K Q2 '24: 886K Q3 '24: 617K Q4 '24: 611K Q1 '25: 488K Q2 '25: 600K Q3 '25: 768K Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Operating Income TTM

-9M -6M -3M 0 3M 6M 9M Q4 '21: -7.5M Q1 '22: -7.1M Q2 '22: -6.6M Q3 '22: -4.5M Q4 '22: -4.5M Q1 '23: -5.1M Q2 '23: -5.6M Q3 '23: -7.1M Q4 '23: -7.2M Q1 '24: -6.4M Q2 '24: -6.3M Q3 '24: -6.7M Q4 '24: -6.4M Q1 '25: -6.5M Q2 '25: -5.9M Q3 '25: -5.1M Q4 '25: -5.1M Q1 '26: -4.9M Q2 '26: -5.3M Q3 '26: -5.4M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Net Income TTM

-9M -6M -3M 0 3M 6M 9M Q4 '21: -7.4M Q1 '22: -7.1M Q2 '22: -6.5M Q3 '22: -4.5M Q4 '22: -4.5M Q1 '23: -5.1M Q2 '23: -5.6M Q3 '23: -7.1M Q4 '23: -7.1M Q1 '24: -6.2M Q2 '24: -6.1M Q3 '24: -6.3M Q4 '24: -6M Q1 '25: -6.2M Q2 '25: -5.6M Q3 '25: -4.8M Q4 '25: -5M Q1 '26: -3.7M Q2 '26: -4M Q3 '26: -4.2M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Cost of Revenue TTM

0 6M 12M 18M Q4 '21: 6.8M Q1 '22: 7.2M Q2 '22: 10M Q3 '22: 12.3M Q4 '22: 15.9M Q1 '23: 16.2M Q2 '23: 13.5M Q3 '23: 8.5M Q4 '23: 4.9M Q1 '24: 4.5M Q2 '24: 4.6M Q3 '24: 4.8M Q4 '24: 4.8M Q1 '25: 5M Q2 '25: 5M Q3 '25: 4.9M Q4 '25: 4.8M Q1 '26: 4.2M Q2 '26: 4.2M Q3 '26: 4.1M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Operating Cash Flow TTM

-9M -6M -3M 0 3M 6M 9M Q4 '20: -4.3M Q1 '21: -5.9M Q2 '21: -6.8M Q3 '21: -7.7M Q4 '21: -5.3M Q1 '22: -3.6M Q2 '22: -952.8K Q3 '22: 2.8M Q4 '23: -5.5M Q1 '24: -5.6M Q2 '24: -5.2M Q3 '24: -5.3M Q4 '24: -5.4M Q1 '25: -5M Q2 '25: -5M Q3 '25: -4.2M Q4 '25: -3.8M Q1 '26: -2.8M Q2 '26: -3M Q3 '26: -3.2M Q1 '21 Q4 '21 Q3 '22 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Free Cash Flow TTM

-9M -6M -3M 0 3M 6M 9M Q1 '19: -2M Q2 '19: -1.9M Q3 '19: -1.7M Q4 '19: -2.3M Q1 '20: -1.6M Q2 '20: -1.7M Q3 '20: -1.8M Q4 '20: -4.3M Q1 '21: -6M Q2 '21: -6.9M Q3 '21: -7.9M Q4 '21: -5.4M Q1 '22: -3.7M Q2 '22: -1M Q3 '22: 2.7M Q4 '23: -5.5M Q1 '24: -5.6M Q2 '24: -5.2M Q3 '24: -5.3M Q4 '24: -5.4M Q2 '19 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '24 Q4 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 6M 12M 18M Q2 '20: 9.8M Q3 '20: 9.8M Q1 '21: 11.7M Q2 '21: 11.8M Q3 '21: 11.9M Q1 '22: 12.4M Q2 '22: 12.6M Q3 '22: 12.8M Q1 '23: 13.1M Q2 '23: 13.5M Q3 '23: 13.5M Q1 '24: 16.8M Q2 '24: 16.8M Q3 '24: 16.8M Q1 '25: 2.1M Q2 '25: 2.1M Q3 '25: 2.4M Q1 '26: 2.6M Q2 '26: 2.9M Q3 '26: 3M Q3 '20 Q3 '21 Q3 '22 Q3 '23 Q3 '24 Q3 '25 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q4 '20: -0.26 Q1 '21: -0.37 Q2 '21: -0.47 Q3 '21: -0.56 Q4 '21: -0.62 Q1 '22: -0.58 Q2 '22: -0.52 Q3 '22: -0.35 Q4 '22: -0.36 Q1 '23: -0.40 Q2 '23: -0.43 Q3 '23: -0.54 Q4 '23: -0.50 Q1 '24: -0.41 Q2 '24: -0.38 Q3 '24: -0.37 Q4 '24: -2.84 Q1 '25: -3.40 Q2 '26: -1.62 Q3 '26: -1.58 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.